Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions

Clicks: 287
ID: 269701
2006
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
The current results indicated that no serious adverse events were associated with rIFN-gamma1b immune enhancement in patients with systemic opportunistic infections who received donor GTX therapy.
Reference Key
a2006cancerrecombinant Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Safdar A;Rodriguez GH;Lichtiger B;Dickey BF;Kontoyiannis DP;Freireich EJ;Shpall EJ;Raad II;Kantarjian HM;Champlin RE;;
Journal cancer
Year 2006
DOI DOI not found
URL
https://www.ncbi.nlm.nih.gov/pubmed/16691620
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome adult female male aged middle aged Child Retrospective Studies drug resistance drug therapy combination dose-response relationship drug combined modality therapy neutropenia / etiology recombinant proteins / adverse effects recombinant proteins / therapeutic use* adrenal cortex hormones / therapeutic use antifungal agents / adverse effects antifungal agents / therapeutic use* gram-negative bacterial infections / complications gram-negative bacterial infections / drug therapy gram-negative bacterial infections / mortality opportunistic infections / drug therapy* hematologic neoplasms / complications* mycoses / complications opportunistic infections / complications amar safdar mycoses / drug therapy* mycoses / mortality interferon-gamma / immunology* pmid:16691620 doi:10.1002/cncr.21929 gilhen h rodriguez richard e champlin antifungal agents / immunology* cytokines / therapeutic use neoplasm granulocytes / transplantation* hematologic neoplasms / therapy interferon-gamma / adverse effects interferon-gamma / therapeutic use* leukocyte transfusion*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.